About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, March 4th, 2013

The QualityStocks
Daily Stock List


Carpathian Gold, Inc. (CPN.TO)

We are highlighting Carpathian Gold, Inc. (CPN.TO), here at the QualityStocks Daily Newsletter.

Based in Toronto, Ontario, Carpathian Gold, Inc. is an exploration and development company. The Company's primary business interest is developing near-term gold production on their 100 percent owned Riacho dos Machados (RDM) Gold Project in Brazil, which is currently focusing on activities surrounding construction. Carpathian Gold's shares trade on the Toronto Stock Exchange.

The Company is also advancing their exploration and development plans on their 100 percent owned Rovina Valley Au-Cu Project (RVP) located in Romania. They believe the Rovina Valley Project will enhance Carpathian Gold's growth profile as a mid-tier gold producer. Their RDM Gold Project is targeted to produce approximately +/-100,000 ounces of gold annually with an anticipated goal for the start of production in the second half of 2013.

Carpathian Gold (on a company wide basis) currently hosts NI 43-101 proven plus probable reserves of 830,200 ounces of gold (proven reserves of 2,300 Kt at 1.30 g/t Au and probable reserves of 18,500 Kt at 1.23 g/t Au). They also host NI 43-101 mineral resources (inclusive of reserves) of approximately 8.1 million ounces of gold in the measured plus indicated categories (RVP: 405.9 million tonnes at 0.55 g/t Au for 7.19 million ounces, RDM: 19.36 million tonnes at 1.50 g/t Au for 0.936 million ounces).

Moreover, they host approximately 0.9 million ounces of gold in the inferred category (RVP: 26.8 million tones at 0.38 g/t Au for 0.33 million ounces, RDM; 9.447 million tones at 1.93 g/t Au for 0.587 million ounces). In addition, they host 1.4 billion pounds of copper in the measured plus indicated category (RVP: 405.9 million tones at 0.16 percent Cu) and 97.0 million pounds of copper in the inferred category (RVP: 405.9 million tonnes at 0.16 percent Cu).

Last week, Carpathian Gold provided an update on their wholly owned Riacho dos Machados Gold Project (RDM). The Project development remains on track for gold production in the second half of 2013 at an annualized rate of approximately 100,000 ounces for an initial period of 8-plus years.

As of the end of February 2013, the construction and development of the project in order to begin the start of gold production is approximately 70 percent complete. The Project will mine 7,000 t/d of ore from an open pit operation. It will treat ore using a standard crush, grind and a CIL processing facility. The assay laboratory is on site and ready to operate.

Carpathian Gold, Inc. (CPN.TO), closed at $0.285, even for the day, on 159,245 volume. The stock's 52-week low/high is $0.24/$0.53.

China YCT International Group, Inc. (CYIG)

Profit Confidential reported previously on China YCT International Group, Inc. (CYIG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

China YCT International Group principally operates through two of their wholly owned subsidiaries. These are Landway Nano Bio-Tech, Inc., incorporated in Delaware and Shandong Spring Pharmaceutical Co., Ltd. (Shandong Spring); incorporated in the People's Republic of China (PRC). China YCT International Group lists on the OTCQB and the Company has their headquarters in Sishui County, PRC.

China YCT, through Shandong Spring, engages in the business of developing, manufacturing and marketing gingko and distributing other dietary supplement products in the PRC. The Company provides Huoliyuan capsules for the treatment of chronic hepatitis, diabetes, insomnia, memory loss, menopause syndrome, and other maladies. In addition, they offer 10 health care supplement products. China YCT markets their products through a network of dealers.

The Company has become a high-tech, global enterprise specializing in the Research and Development (R&D), production and sales of Gingko nutraceutical health products. Currently, China YCT has more than 30 branches in China, as well as a branch in Russia, and over 300 distributors.

The Company entered into a purchase and sale contract with Shandong Yong Chun Tang (Shandong YCT) on December 26, 2006. The contract sets forth the wholesale price that China YCT pays to Shandong YCT for distributing their products. On February 9, 2010, China YCT renewed the Purchase and Sale Contract with Shandong YCT for a term of five years ending on February 28, 2015. Therefore, the Company can purchase 10 types of health care supplement products from Shandong YCT on a fixed price, which was selected according to their sales volume and profit margin. For the three months ended December 31, 2012, 38.1 percent of China YCT's revenue was from the sale of the health care supplement products, compared to 33.6 percent in the same period in 2011.

Since September 2009, China YCT began to engage in the production and distribution of their non-prescription drug, Huoliyuan Capsule, which is patented in China; they developed distribution channels for the drug. The Company's sales have increased since September 2009 because of the establishment of their manufacturing and distribution channels of Huoliyuan Capsule.

Since July 2010, they changed from being solely a distributor of Shandong YCT to both a manufacturer and distributor of their own products, the Huoliyuan Capsules. Consequently, they obtained new customers and expanded their sales of Huoliyuan Capsules. The Huoliyuan Capsule product accounted for 59.6 percent of the Company's revenue for the three months ended December 31, 2012. This is in comparison to 61.2 percent for the same period in 2011.

China YCT International Group, Inc. (CYIG), closed Monday's trading session at $1.40, up 46,566.67%, on 856,890 volume with 1,019 trades. The average volume for the last 60 days is 2,280 and the stock's 52-week low/high is $0.003/$0.85.

Green Innovations Ltd. (GNIN)

Greenbackers, Penny Stock Rumble, Global Equity Alert, FeedBlitz, and Real Pennies reported recently on Green Innovations Ltd. (GNIN), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 2012, Green Innovations Ltd., through their wholly owned subsidiary Green Hygienics, Inc., is the exclusive licensed North American distributor of American Hygienics Corp.'s 100 percent tree-free bamboo-based product line. This includes personal care and paper-based goods. Green Innovations' corporate focus is on filling a void in the eco-friendly, biodegradable product group.  The Company has their headquarters in Miami, Florida. Green Innovations' lists on the OTC Markets' OTCQB. 

Green Innovations provides consumers the opportunity to enjoy high-quality and performance eco-friendly goods from dedicated experts who have been producing bamboo products for more than a decade, along with the cost-benefit of local raw material manufacturing. Their products include Toilet Rolls, Cosmetic Wipes and Pads, Facial Tissue, and copy paper, notebooks and office papers - all of 100 percent bamboo pulp. Products also include meat platters (bamboo-Styrofoam) for ground beef, steaks, etc., Female Sanitary Pads, and Panty Liners.

Last week, Green Innovations announced that their subsidiary, Green Hygienics intends to expand further their current product offerings to include a selection of premium grade automotive care and cleaning products. Green Hygienics is considering a broad array of automotive care and cleaning products for addition to their product family. These include windscreen and glass wipes, leather protectant, grease remover wipes, dashboard and trim wipes, tar and bug remover wipes, as well as tire wipes. Each automotive wipe product can be made from traditional sourced paper or 100 percent biodegradable organically grown bamboo.

Today, Green Innovations announced that Green Hygienics is currently in the process of obtaining final approval for several of their flagship products to undergo distribution by Federated Group, a leading grocery private label brand developer, owner, and marketer in the U.S. Federated Group has grown into one of the largest wholesale buying groups in the U.S.  Federated Group's food service buying division consolidates products for supply to some of the largest wholesalers and grocery distribution chains.

Green Innovations Ltd. (GNIN), closed Monday's trading at $1.10, down 6.78%, on 11,332,019 volume with 5,866 trades. The average volume for the last 60 days is 1,449,354 and the stock's 52-week low/high is $0.17/$3.35.

Berjaya Sports Toto Berhad (BJSAF)

Today we are reporting on Berjaya Sports Toto Berhad (BJSAF), here at the QualityStocks Daily Newsletter.

Berjaya Sports Toto Berhad (Berjaya Corporation Berhad) is an investment holding company that engages in the operation of Toto betting in Malaysia. They additionally engage in the lease of online lottery equipment; the provision of software support; the manufacture and distribution of computerized lottery and voting systems; and property investment and development activities. Furthermore, they operate health and fitness centers, and hotels, as well as offers computer consultancy services. The Company lists on the OTC Pink Current Information. Berjaya Sports Toto Berhad (Berjaya Corporation Berhad) is based in Kuala Lumpur, Malaysia.

Incorporated in 1969, Berjaya is one of Asia's largest conglomerates. They have diversified interest across a number of business sectors. The Company employs 16,000 people. The core businesses of Berjaya include Consumer Marketing, Direct Selling & Retail; Financial Services; Hotels, Resorts, Vacation Timeshare & Recreation Development, and Property Investment and Development. They also include Gaming & Lottery Management; Development of Sanitary Landfill, Environmental Services and clean Technology Investment; Food & Beverage, and Investment Holding and others.

Berjaya Corporation Berhad's different businesses are held through several listed companies (subsidiaries), which include Berjaya Land Berhad, Berjaya Food Berhad (BFood), and Berjaya Sports Toto Berhad (B-Toto). Related companies include Berjaya Media Berhad and Berjaya Assets Berhad (formerly known as Matrix International Berhad).

In September 2012, Berjaya Kyoto Development Kabushiki Kaisha (Berjaya Kyoto), a wholly-owned subsidiary of Berjaya Land Berhad
(B-Land), which in turn is a subsidiary of Berjaya Corporation Berhad (BCorp), announced that they executed an agreement with Four Seasons Hotels and Resorts for the management of a luxury hotel development in Kyoto.

The Four Seasons Hotel Kyoto will be B-Land's signature and flagship development in Japan and will be built on a 20,478 square meter (approximately 5 acre) site in the historical core of Higashiyama-ku amid the temples and heritage sites of Kyoto. The property will have an estimated built-up area of 8,106 square meters consisting of 186 keys and be built with a fusion of modern luxuries and traditional Japanese design. The Hotel's facilities will include a banquet hall, restaurants, bar, swimming pool, fitness gym, spa, sundries shop and abundant parking bays.

Berjaya Sports Toto Berhad (BJSAF), closed Monday's trading session at $1.3963, even for the day, on 2,800,290 volume with 162 trades. The average volume for the last 60 days is 4,930,300 and the stock's 52-week low/high is $0.0275/$0.155.

China Education Alliance, Inc. (CEAI)

Uncommon Wisdom and PennyTrader Publisher reported earlier on China Education Alliance, Inc. (CEAI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

China Education Alliance, Inc. is a foremost educational service company whose shares trade on the OTCQX U.S. The Company offers high-quality online education materials and on-site training and tutoring to students aged 6 to 18 and adults (university students and professionals) aged 18 and over in China. China Education Alliance distributes online test preparation materials, researchers' materials; study guides, audio recordings, and provides vocational skills and certifications training. China Education Alliance has their corporate headquarters in Harbin, The People's Republic of China (PRC).

China Education Alliance has teaching centers located across China. Their business model is divided into two segments - students and graduate professionals. The design of the Company's business model is to deliver the skills and knowledge necessary to excel in a fast-growing and highly competitive China.

The Company provides students in the first segment with online education materials sourced from top tier schools and eminent instructors for download, as well as online training and tutoring services. China Education additionally offers hands on training and tutoring to aid Chinese students pass the senior high school entrance and college entrance exams. In the second segment for graduates and professionals, the Company provides vocational training courses in subjects including Information Technology (IT), administration, multimedia, and a number of professional training programs.

China Education Alliance markets their database of over 350,000 exams and test papers and courseware for college, secondary and elementary schools, under the "Famed Instructors Test Paper Store" via their website, www.edu-chn.com. In addition, the Company provides on-site exam-oriented after-school training and tutoring services called "The Big Classroom of the Famous Instructors". They developed a new online educational game "Fortune Island" recommended and approved by the "National Educational Game Research Base" a division of the Chinese Ministry of Education.

Furthermore, the Company owns part of the "Scientific Discovery" newspaper. This newspaper provides them with another distribution channel for their educational content.

China Education Alliance provides vocational training and vocational performance evaluation metrics services, and employment education via their "Millions of College Students Employment Crossroad" program through collaborating with the National Association of Vocational Education of China (NAVEC) to set up, www.360ve.com. China Education Alliance operates NAVEC's Education Examination Center. Moreover, they develop vocational training programs through collaborating with other educational institutions.

China Education Alliance, Inc. (CEAI), closed Monday's trading session at $0.67, up 8.06%, on 13,257 volume with 7 trades. The average volume for the last 60 days is 6,332 and the stock's 52-week low/high is $0.21/$1.56.

Richfield Oil & Gas Co. (ROIL)

FeedBlitz reported recently on Richfield Oil & Gas Co. (ROIL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Richfield Oil & Gas Co. is an independent oil and natural gas company that lists on the OTC Markets' OTCQX U.S. Premier. The Company has substantially all of their producing assets located in Kansas with additional leasehold assets in Utah and Wyoming. Founded in April 2011, Richfield is working to acquire assets within their areas of focus that have been determined to be low-risk development properties. Richfield Oil & Gas has their headquarters in Salt Lake City, Utah.

The Company evaluates potential acquisitions by analyzing each wellbore in each field to identify upside potential. Richfield continues to develop and grow organically via the exploitation and development of their existing field inventory using drilling, workover, recompletion and other lower-risk development projects to increase reserves and production.

Richfield Oil & Gas' team of industry professionals has experience in analyzing the initial remaining reserve potential and uses their collective knowledge and experience to develop unrealized or underestimated value through recompletions in existing wellbores, optimized facility management, as well as low-risk development drilling. The Company believes that their approach extends the economic life of fields and allows them to increase the value of production for delivery to U.S. energy markets.

The Company's portfolio of oil and gas properties in Utah, Wyoming, Kansas and Oklahoma cover three major geographic areas of operation. These include the Mid-Continent, the Utah-Wyoming Overthrust, and the Central Utah Overthrust. The Company's Mid-Continent operations cover approximately 3,000 acres in six fields in central and southern Kansas, and northern Oklahoma - primarily in the Central Kansas Uplift (CKU). Richfield's primary targets are the prolific Wilcox and Arbuckle formations.

Last week, Richfield Oil & Gas announced results of their drilling and general field operations in the South Haven Field located in Sumner County, Kansas. They completed the drilling and completion of the RFO Helsel #3-1 well, the recompletion of the Rusk #2 well, and the drilling, permitting, and completion of the Yearout #1 SWD (salt-water disposal) well. Road boring, pipeline and production facilities construction and other general field operations have been ongoing since December 2012. Richfield is the 100 percent working interest (WI) owner and the operator of the South Haven Field.

Richfield Oil & Gas Co. (ROIL), closed Monday's trading session at $1.13, down 5.83%, on 2,400 volume with 3 trades. The average volume for the last 60 days is 3,037 and the stock's 52-week low/high is $1.10/$3.50.

Cantex Mine Development Corp. (CD.V)

Today we are reporting on Cantex Mine Development Corp. (CD.V), here at the QualityStocks Daily Newsletter.

Cantex Mine Development Corp. engages in the acquisition and exploration of mineral properties for commercial mineral deposits. Their main project is in northwestern Yemen where the Company owns exclusive exploration licenses over a 1,583 square kilometer area. Cantex primarily explores for copper, cobalt, platinum, nickel, and gold deposits. Cantex Mine Development lists on the TSX Venture Exchange; the Company is based in Kelowna, British Columbia.

In Yemen, Nickel, Copper, Cobalt and Platinum have been discovered on three of Cantex's licenses at Suwar, Wadi Qutabah and Al Masna. The Suwar nickel, copper, cobalt, platinum project is in the southern part of a layered basic igneous complex approximately 32 km in length and 8 km in width. The Wadi Qutabah nickel, copper, cobalt, platinum project is in the northern part of the same-layered mafic complex that hosts the Suwar nickel deposit. The Al Masna nickel, copper, cobalt project is in the Saadah region approximately 205 km north-northwest of the capital city, Sana'a, and 25 km south of the border with Saudi Arabia.

A gold deposit has been discovered on the Company's Al Hariqah project. Al Hariqah is a near-surface gold deposit located 130 km NW of Sana'a, Yemen (NW Yemen).  Cantex owns the Project 100 percent.

Cantex also has a 100 percent interest in 6 gold exploration prospects secured with 140 claims, in Nevada. The Company has five drill ready properties in Nevada along known trends of gold mines and is presently seeking joint venture partners to advance the projects. Furthermore, the Company also has 10 claim blocks covering approximately 30,000 hectares around a new belt of gold mineralization discovered approximately 100 kilometers northeast of Mayo, Yukon Territory.

In January 2013, Cantex Mine Development provided an update on their exploration projects in Yemen and the Yukon. Concerning their Yukon Gold Program, the processing and preparation of 1,392 heavy mineral samples collected from unstaked areas and within the Company's 8 claim blocks totaling 1,380 claims covering over 28,000 hectares, is complete at CF Mineral Research Ltd. in Kelowna.  The samples have been submitted for analysis in Vancouver to test for gold and key pathfinder elements.

Concerning their Yemen Gold Program, drilling continues at their Al Hariqah gold project that has been optioned by WCP Resources Ltd. of Australia.  Two core drills are now testing the southern extension of the deposit.

Cantex Mine Development Corp. (CD.V), closed Monday's session at $0.015, even for the day, on 10,000 volume. The stock's 52-week low/high is $0.01/$0.07.

Red Eagle Mining Corp. (RDEMF)

We are highlighting Red Eagle Mining Corp. (RDEMF) today, here at the QualityStocks Daily Newsletter.

Red Eagle Mining Corp. is a gold exploration and development company that lists on the OTCQX International. Currently, the Company is developing the 390-km² Santa Rosa Gold Project in Antioquia, Colombia. In addition, Red Eagle Mining holds an extensive package of exploration ground in Colombia, including the Pavo Real Gold Project. The Company has their headquarters in Vancouver, British Columbia.

The Santa Rosa Gold Project is an intrusive hosted structurally controlled quartz stockwork system within the prolific Antioquia Batholith. Santa Rosa is 70 kilometers north of Medellin near the town of Santa Rosa de Osos. This region has excellent infrastructure. Santa Rosa is also situated approximately 30km west of AngloGold Ashanti's Gramalote gold deposit (2.5 million ounce M&I resource grading 0.8 g/t Au) and 40km east of Continental Gold's Buritica gold deposit (1.6 million ounce M&I resource grading 13.6 g/t Au).

The Pavo Real project is within the Department of Tolima, 20 kilometers south of the city of Ibague and 45 kilometers southeast of AngloGold Ashanti's La Colosa project. The project is easily accessible by road; infrastructure is readily available as well. The Pavo Real project offers the potential for a large sedimentary-hosted gold deposit in quartz carbonate vein clusters. Pavo Real is a joint venture (JV) with Miranda Gold. Under this JV, Red Eagle Mining can earn-in to 70 percent of the project by completing a feasibility study.

Today, Red Eagle Mining announced assay results from the Phase Four drill program at the San Ramon Deposit, Santa Rosa Gold Project, Antioquia, Colombia. Highlights from the initial 46 drill holes (SR-140 to SR-185) include intercepts SR-142 - 54.2m at 0.77 g/t Au from 354.4m down hole;  SR-146 - 46.5m at 0.93 g/t Au from 105.8m down hole (incl. 0.8m at 27.20 g/t Au);  SR-168 - 36.1m at 2.64 g/t Au from 392.5m down hole (incl. 1.5m at 34.34 g/t Au);  SR-172 - 0.6m at 157.70 g/t Au from 398.4m down hole, and SR-175 - 4.1m at 12.75 g/t Au from 117.7m down hole (incl. 1.7m at 25.47 g/t Au).

Highlights additionally include intercepts SR-177 - 37.5m at 1.27 g/t Au from 69.5m down hole (incl. 0.5m at 43.90 g/t Au);  SR-181 - 7.3m at 6.08 g/t Au from 148.3m down hole (incl. 0.8m at 35.90 g/t Au);  SR-182 - 0.8m at 36.30 g/t Au from 55.5m down hole; SR-184 - 28.8m at 1.54 g/t Au from 178.0m down hole, and  SR-185 - 14.3m at 2.74 g/t Au from 46.7m down hole (incl. 0.9m at 30.90 g/t Au).

Red Eagle Mining Corp. (RDEMF), closed Monday's session at $0.45, up 7.53%, on 40,000 volume with 10 trades. The average volume for the last 60 days is 4,758 and the stock's 52-week low/high is $0.2595/$0.831.


The QualityStocks
Company Corner


VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, up 25.00%, on 3,500 volume with 6 trades. The stock’s average daily volume over the past 60 days is 2,997, and its 52-week low/high is $0.06/$3.05.

VistaGen Therapeutics, Inc. reported entry today into a comprehensive new strategic collaboration agreement designed to characterize and functionally benchmark VistaGen's human liver cell platform, LiverSafe 3D™, for studying and predicting human liver drug metabolism. The agreement is with premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction, and toxicity screening, Celsis In Vitro Technologies, whose experience in and expertise with in vitro drug metabolism will help rapidly accelerate VSTA's technology roadmap. The agreement once again shows the company's firm commitment to advancing the power of human pluripotent stem cells as a basis of more predictive in vitro tools for drug discovery and development.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D™

VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System

Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101

The Guitammer Company Inc. (GTMM)

The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.165, up 3.12%, on 55,000 volume with 7 trades. The stock’s average daily volume over the past 60 days is 16,316, and its 52-week low/high is $0.082/$0.35.

The Guitammer Company Inc. named 25-year furniture industry veteran Mark E. Barr to the National Sales Manager position today for the company's Home Theater wing. A shrewd move by industry top dog in low frequency sound and creator of the award-winning line of ButtKicker®-brand low frequency audio transducers, which provide an immersive "4D" entertainment experience. Mark should prove indispensible to GTMM moving forward as a key player in their North American sales strategy, primarily focusing on the OEM, retail and installer markets.

The Guitammer Company Inc. (GTMM) is a leader in low frequency sound products and technology. Its innovative and award winning line of patented ButtKicker-brand low frequency audio transducers let users feel low-frequency sound (bass). ButtKicker brand products are used around the world by leading entertainment and theater companies such as AMC, IMAX and Disney in movie theaters and attractions; by world-famous musicians; in home theaters, simulators and for car audio.

ButtKicker brand products are distributed by Pearl Drums for musicians under the trade name, "Pearl's Throne Thumper by ButtKicker", and factory installed in home theater seating by Palliser Furniture. ButtKicker brand products' patented design makes them musically accurate, powerful and virtually indestructible. The Company is headquartered in Westerville, OH.

The Guitammer Company's newly patented broadcast technology, ButtKicker LIVE! enables the excitement, impact and feeling of sporting events to be broadcast along with the sound and video. ButtKicker LIVE! puts you into the action, whether you're at home or at the event.

ButtKicker Live! technology is available for cable, satellite, fiber optic, IPTV and over-the-air broadcast and has been successfully tested with several major content (sports) providers. ButtKicker(r) and ButtKicker Live!(r) are registered trademarks of The Guitammer Company. Disclaimer

The Guitammer Company Inc. Company Blog

The Guitammer Company Inc. News:

Guitammer Names National Sales Manager - Home Theater

Guitammer Joins Nationwide, North America's Largest Buying and Marketing Organization

Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases

Rainbow Coral Corp. (RBCC)

The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.2867, off by 7.96%, on 86,872 volume with 28 trades. The stock’s average daily volume over the past 60 days is 115,995, and its 52-week low/high is $0.27/$2.67.

Rainbow Coral Corp., a rising star of the over $84.6B global biotech space, reported engagement today of Scottsdale, Arizona-based free collator of data from hundreds of Small-Cap online Investment Newsletters and investor communications specialists, QualityStocks. The ground-breaking work being advanced by RBCC through the company's wholly-owned Rainbow Biosciences subsidiary, via a model focused on short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer, will be prominently featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and Message Boards.

Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.

Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.

The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer

Rainbow Coral Corp. Company Blog

Rainbow Coral Corp. News:

Rainbow Coral Corp. (RBCC) Announces Engagement of QualityStocks Investor Relations Services

RBCC Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion Drug Delivery Market

RBCC Retains New IR Group to Optimize Investor Outreach, Relay Key Growth Plans

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.116, up 11.54%, on 2,800,290 volume with 162 trades. The stock’s average daily volume over the past 60 days is 4,930,300, and its 52-week low/high is $0.0275/$0.155.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis to Provide 2013 Business Outlook on March 6, 2013

Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group

Chairman and CEO of Advaxis Featured in Exclusive SmallCapVoice Interview

VistaGen Therapeutics, Inc. (VSTA) to Further Advance LiverSafe 3D™ Technology via Strategic Collaboration with Celsis

Today before the opening bell, VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, announced it has entered a new collaboration agreement with Celsis In Vitro Technologies (“Celsis”), the premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction, and toxicity screening. The two companies aim to characterize and functionally benchmark VistaGen’s human liver cell platform, LiverSafe 3D™, for studying and predicting human liver drug metabolism.

Utilizing Celsis’ experience and expertise in in vitro drug metabolism, VistaGen aims to demonstrate the accuracy of its human liver cell platform. In this strategic collaboration Celsis will not only validate VistaGen’s stem cell-derived liver cells in traditional pharmaceutical metabolism assays, but will also determine genetic variations in VistaGen’s pluripotent stem cell lines that are important to drug development. VistaGen also will utilize Celsis’ human cadaver-derived liver cells, currently used throughout the pharmaceutical industry for traditional drug metabolism assays, as reference controls with which to monitor and benchmark the functional properties of LiverSafe 3D™.

With the assistance of Celsis scientists, VistaGen aims to achieve four key objectives:

• Optimize techniques to handle and maintain primary human cadaveric liver cells as reference controls for various drug development assays;
• Develop a stable supply of characterized and validated human cadaveric liver cells to serve as internal controls and provide benchmark comparisons for the characterization of VistaGen’s pluripotent stem cell-derived liver cells;
• Characterize VistaGen’s liver cells using many of the same industry standardized assays used to characterize primary human cadaveric liver cells; and
• Produce a joint publication of the characterization of VistaGen’s stem cell-derived human liver cells.

“As an industry leader in the development of in vitro primary hepatocyte technology, Celsis has extensive resources to aid us in the benchmarking of our novel liver cell-based platform to industry standards,” stated H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer. “We anticipate this collaboration will lead to the further validation of our LiverSafe 3D™ system for predicting liver toxicity and drug metabolism issues long before costly human clinical trials.”

“This is another example of our long-term dedication to using the power of human pluripotent stem cells as the basis of more predictive in vitro tools for drug discovery and development,” concluded Dr. Snodgrass.

For additional information, visit www.VistaGen.com

The Guitammer Company, Inc. (GTMM) Beefs-up ButtKicker Sales Initiatives with New National Sales Manager

The Guitammer Company, a low frequency sound products and technology company, has appointed furniture industry veteran Mark E. Barr as the new national sales manager for the company’s Home Theater division.

Barr will use his more than 25 years of experience as a retail store owner to oversee Guitammer’s North American home theater sales of ButtKicker® brand products, the company’s patented line of low frequency audio transducers.

As national sales manager, Barr will also manage Guitammer’s new partnership with Nationwide, North America’s largest buying group operating more than 10,000 store fronts in various furniture, appliance, and rent-to-own markets.

Barr previously served as president of Barr’s, Inc., where he led the company from a single store operation to a multi-unit regional retailer. He anticipates leveraging this industry knowledge to strengthen Guitammer’s sales growth.

“I am extremely excited to join the Guitammer team and am prepared to use my perspective as a former retailer to ensure that our products and programs are what our retail partners need to thrive in today’s marketplace,” Barr stated in the press release. “As Guitammer continues to grow, my focus will be on increasing ButtKicker brand home theater sales in the U.S. and Canada. I believe my background as a successful entrepreneur in the retail business makes me ideally suited to convey ButtKicker’s value proposition to the home theater sales channel. I am very excited by this opportunity and look forward to contributing in a significant way to Guitammer’s future success.”

For more information visit www.guitammer.com and www.thebuttkicker.com

Rainbow Coral Corp. (RBCC) Engages QualityStocks Investor Relations Services

Rainbow Coral just announced that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today’s leading-edge research into practical, affordable treatments for people who need them most.

Rainbow Coral’s pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer’s clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

Patrick Brown, CEO of Rainbow Coral, stated, “RBCC has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter, Video and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”

For more information, visit www.RBCC.QualityStocks.net

GlobalWise Investments, Inc. (GWIV) Rides the Cloud Revolution

GlobalWise Investments, providing businesses and organizations with the latest in ECM (Enterprise Content Management) solutions via its subsidiary Intellinetics, is sitting on top of one of the biggest movements in the evolution of computers.

Cloud technology, essentially the offering/utilization of remotely based hardware and software capabilities, has transformed the way we view computer processing. Although the concept of services being shared on a global basis is not new, advancements in communication and processing technology have given it a role few would have imagined in previous decades. Today the cost and efficiency benefits of cloud processing are fueling a revolution, as more and more businesses are turning to the kind of cloud-based services exemplified by GlobalWise.

A recent report from Gartner (http://dtg.fm/9lX9) indicates that public cloud services are expected to grow by over 18% in 2013, to $131 billion, with infrastructure services, such as computing, storage, and print services, jumping an imposing 47%. Advertising is still the biggest cloud services segment, according to Gartner, with $310 billion expected to be spent between now and 2016. However, the report emphasizes that a “strong demand is anticipated for all types of cloud service offerings,” with North America representing the largest region in the cloud services market.

GlobalWise subsidiary Intellinetics provides businesses and organizations the latest in ECM capability, covering virtually any type of document, with its cloud technology ensuring high-speed and secured document access 24/7 from anyplace in the world. The company’s open software and business service provider partnerships are designed to capture a major portion of the underserved and compliance-heavy SMB market. Underpinning all of this is the rapidly expanding cloud market which is itself going global.

For additional information, visit www.GlobalWiseInvestments.com and www.Intellinetics.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Real Pennies


Stock Roach

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251